Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American Association for Cancer Research (AACR) Meeting

Tekmira Presents Data From Its TKM-PLK1 Phase I Clinical Trial at American
Association for Cancer Research (AACR) Meeting

 TKM-PLK1 Resulted in Clinical Benefit in 44% of Evaluable Patients Receiving
                           Doses in Effective Range

 Tekmira to Initiate a Phase II Clinical Trial in Gastrointestinal Carcinoid
                           (Neuroendocrine) Cancer

                     Conference Call at 4:30 pm ET Today

VANCOUVER, B.C., April 9, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals
Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference
(RNAi) therapeutics, announced the results of its Phase I clinical trial with
TKM-PLK1, an RNAi therapeutic for the treatment of solid tumors. The data are
being presented today at 3:30 pm ET at the annual meeting of the American
Association for Cancer Research (AACR) in an oral presentation entitled "A
phase I dose escalation study of TKM-080301, a RNAi therapeutic directed
against PLK1, in patients with advanced solid tumors." In this Phase I study,
TKM-PLK1 was generally well-tolerated and showed encouraging signs of drug
activity with RNAi activity confirmed in tumor biopsy.

"We are very pleased with the results of our TKM-PLK1 Phase I clinical trial
in a population of advanced cancer patients with solid tumors. The data
generated from this clinical trial demonstrated that TKM-PLK1 was generally
well-tolerated. In particular, we are very encouraged that four out of nine
(44%) evaluable patients treated at doses in a range consistent with
preclinical efficacy showed clinical benefit. In addition, we have confirmed
RNAi activity in tumor biopsy. A variety of tumor types were treated in this
Phase I study, but of particular note, of the two patients enrolled with
gastrointestinal carcinoid (neuroendocrine) cancer, both responded to
treatment with TKM-PLK1, and we look forward to initiating a Phase II clinical
trial in this indication where there is a significant unmet medical need,"
said Dr. Mark J. Murray, Tekmira's President and CEO.

TKM-PLK1, which employs a unique lipid nanoparticle (LNP) formulation for
oncology applications, was administered to 24 patients at doses ranging from
0.15 mg/kg to 0.90 mg/kg; with a total of 152 doses administered and a mean
number of 6.2 doses per patient (range of 1-31 doses). The most common grade
1-2 adverse events were rigors (33%) and fever (25%). No dose-dependent
changes in liver function tests were observed. Dose-limiting toxicities
included: one grade 3 transient thrombocytopenia in one patient (at 0.9 mg/kg)
and one grade 3 hypoxia/dyspnea in another patient (at 0.9 mg/kg). Based on
these data, the maximum tolerated dose is estimated to be 0.75 mg/kg. A
10-patient expansion cohort is currently enrolling patients at 0.75 mg/kg,
with data expected later this year.

Patients had a mean of 5.1 prior treatment regimens (range of 1-14).
Forty-four percent (4 out of 9) patients evaluable for response, treated at a
dose equal to or greater than 0.6 mg/kg, showed clinical benefit. In
particular, one patient with progressive, metastatic appendiceal carcinoid
(neuroendocrine) cancer had a durable partial tumor response based on RECIST
criteria, continuing for more than 10 months. Three other patients achieved
stable disease, including one patient with metastatic appendiceal carcinoid
(neuroendocrine) cancer, another patient with metastatic colorectal cancer,
and a third patient with metastatic adrenocortical carcinoma.

"PLK1 has been a target of interest for years, and we know from the medical
literature that patients with elevated levels of PLK1 in their tumors exhibit
poorer prognosis and survival rates. By using an RNAi approach and exploiting
its naturally occurring mechanism of action, we can potentially overcome the
limitations of other approaches and effectively silence PLK1. The safety data,
drug activity and anti-tumor activity with TKM-PLK1 are encouraging, and I
look forward to the further development of this promising therapeutic," said
Dr. Ramesh K. Ramanathan, Medical Director of the Virginia G. Piper Cancer
Center Clinical Trials Program at Scottsdale Healthcare and deputy director of
the Clinical Translational Research Division of the Translational Genomics
Research Institute (TGen) in Phoenix, Arizona.

Patients were dosed on a weekly protocol with each four week cycle consisting
of three once weekly doses followed by a rest week. Pharmacokinetic data
showed that Cmax (peak serum concentration of drug) and area under the curve
(AUC) were dose proportional, without evidence of drug accumulation, and that
the pharmacokinetic profile of TKM-PLK1 is maintained through multiple cycles.
Pre-clinical animal pharmacokinetic data were predictive for the observed
results in humans. Importantly, the data confirm that the drug exposure levels
achieved in this trial, incorporating Tekmira's proprietary LNP formulation
specifically designed to facilitate siRNA delivery to disseminated disease
sites, are several fold greater than were achieved in clinical trials using
earlier LNP formulations.

TKM-PLK1 Phase II Clinical Trial

Tekmira expects to initiate a Phase II clinical trial in patients with
previously treated gastrointestinal carcinoid (neuroendocrine) cancer in the
second half of 2013. Details of the trial design will be disclosed later this
year. Tekmira is also evaluating additional indications for Phase II
development and will provide guidance later this year. Tekmira also expects to
present data from the expansion cohort of the TKM-PLK1 Phase I clinical trial
this year.

About Gastrointestinal Carcinoid (Neuroendocrine) Tumors

Neuroendocrine tumors (NETs) consist of a spectrum of malignancies that can
arise from neuroendocrine cells throughout the body. These tumors are
characterized by their ability to produce peptides that cause characteristic
hormonal syndromes. Metastatic gastrointestinal carcinoid (neuroendocrine)
tumors often have a poor prognosis and may have an aggressive clinical course.
It is estimated that more than 12,000 new cases of carcinoid/NETs are
diagnosed each year, and at least 115,000 people are living with
carcinoid/NETs in the United States. The treatment of patients with
gastrointestinal neuroendocrine tumors remains a challenge with few treatment
options available.

About TKM-PLK1 Phase I Study Design

The TKM-PLK1 Phase I clinical trial, conducted at oncology centers in the
United States, was an open label, multi-dose, dose escalation study designed
to evaluate the safety, tolerability and pharmacokinetics of TKM-PLK1 as well
as determine the maximum tolerated dose. Secondary objectives of the trial are
to measure tumor response and the pharmacodynamic effects of TKM-PLK1 in
patients providing biopsies.

Conference Call Information

Tekmira will hold a conference call and webcast today (Tuesday, April 9, 2013)
at 1:30 pm Pacific Time (4:30 pm Eastern Time) to discuss results of the
TMK-PLK1 Phase I clinical trial. A live audio webcast of the call can be
accessed through the Investor section of Tekmira's website at
www.tekmirapharm.com. Or, alternatively, to dial into the conference call,
please call 914-495-8556 or 1-866-393-1607.

An archived webcast of this conference call will be available on the Tekmira
website approximately two hours after the event. Or alternatively, you may
access a replay of the conference call by calling 404-537-3406 or
1-855-859-2056 and referencing conference ID 33014753.

About RNAi and Tekmira's LNP

RNAi therapeutics have the potential to treat a broad number of human diseases
by "silencing" disease causing genes. The discoverers of RNAi, a gene
silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for
Physiology or Medicine. RNAi therapeutics, such as "siRNAs," require delivery
technology to be effective systemically. Tekmira believes its LNP technology
represents the most widely adopted delivery technology for the systemic
delivery of RNAi therapeutics. Tekmira's LNP platform is being utilized in
multiple clinical trials by both Tekmira and its partners. Tekmira's LNP
technology (formerly referred to as stable nucleic acid-lipid particles or
SNALP) encapsulates siRNAs with high efficiency in uniform lipid nanoparticles
that are effective in delivering RNAi therapeutics to disease sites in
numerous preclinical models. Tekmira's LNP formulations are manufactured by a
proprietary method which is robust, scalable and highly reproducible, and
LNP-based products have been reviewed by multiple FDA divisions for use in
clinical trials. LNP formulations comprise several lipid components that can
be adjusted to suit the specific application.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on
advancing novel RNAi therapeutics and providing its leading lipid nanoparticle
delivery technology to pharmaceutical partners. Tekmira has been working in
the field of nucleic acid delivery for over a decade and has broad
intellectual property covering LNPs. Further information about Tekmira can be
found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

Forward-Looking Statements and Information

This news release contains "forward-looking statements" or "forward-looking
information" within the meaning of applicable securities laws (collectively,
"forward-looking statements"). Forward-looking statements are generally
identifiable by use of the words "believes," "may," "plans," "will,"
"anticipates," "intends," "budgets," "could," "estimates," "expects,"
"forecasts," "projects" and similar expressions, and the negative of such
expressions. Forward-looking statements in this news release include
statements about Tekmira's strategy, future operations, clinical trials,
prospects and the plans of management; RNAi (ribonucleic acid interference)
product development programs; the results of the Phase I clinical trial with
TKM-PLK1; and the effects of Tekmira's products on the treatment of cancer,
including gastrointestinal carcinoid (neuroendocrine) tumors; the expected
completion and release of data from the expansion cohort of the TKM-PLK1 Phase
I clinical trial later this year; the evaluation of additional indications for
Phse II development, and guidance thereon; and, the expected timing of the
release of details about, and the initiation of, a Phase II clinical trial for

With respect to the forward-looking statements contained in this news release,
Tekmira has made numerous assumptions regarding, among other things: LNP's
status as a leading RNAi delivery technology; the effectiveness of Tekmira's
products as a treatment for cancer, including gastrointestinal carcinoid
(neuroendocrine) cancer; results in preclinical models are indicative of the
potential effect in humans; Tekmira's research and development capabilities
and resources; FDA approval with respect to commencing clinical trials; the
timing and obtaining of regulatory approvals for Tekmira's products; the time
required to complete research and product development activities; and
Tekmira's ability to protect its intellectual property rights and not to
infringe on the intellectual property rights of others. While Tekmira
considers these assumptions to be reasonable, these assumptions are inherently
subject to significant business, economic, competitive, market and social
uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause
Tekmira's actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or
implied by the forward-looking statements contained herein. Known risk factors
include, among others: the completion of and timing of the release of the data
from the expansion cohort of the TKM-PLK1 Phase I clinical trial may not occur
as anticipated, or at all; Tekmira might not release details about the
TKM-PLK1 Phase II trial design in the timeframe anticipated, or at all;
TKM-PLK1 might not enter into Phase II clinical trials in the timeframe
anticipated, or at all; Tekmira's ability to obtain and protect intellectual
property rights, and operate without infringing on the intellectual property
rights of others; Tekmira's research and development capabilities and
resources will not meet current or expected demand; Tekmira's products may not
prove to be effective in the treatment of cancer, including gastrointestinal
carcinoid (neuroendocrine) tumors; the possibility that other organizations
have made advancements in RNAi delivery technology that Tekmira is not aware
of; the FDA will not approve the commencement of Tekmira's planned clinical
trials or approve the use of Tekmira's products and generally, difficulties or
delays in the progress, timing and results of clinical trials; the FDA may
determine that the design and planned analysis of Tekmira's clinical trials do
not adequately address the trial objectives in support of Tekmira's regulatory
submissions; pre-clinical and clinical trials may be more costly or take
longer to complete than anticipated; pre-clinical or clinical trials may not
generate results that warrant future development of the tested drug candidate;
and the possibility that Tekmira has not sufficiently budgeted for
expenditures necessary to carry out planned activities.

A more complete discussion of the risks and uncertainties facing Tekmira
appears in Tekmira's annual report on Form 20-F for the year ended December
31, 2012 (Annual Report), which is available at www.sedar.com or at
www.sec.gov/edgar.shtml. All forward-looking statements herein are qualified
in their entirety by this cautionary statement, and Tekmira disclaims any
obligation to revise or update any such forward-looking statements or to
publicly announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or developments,
except as required by law.

CONTACT: Investors
         Jodi Regts
         Director, Investor Relations
         Phone: 604-419-3234
         Email: jregts@tekmirapharm.com
         David Ryan
         Longview Communications Inc.
         Phone: 416-669-7906
         Email: dryan@longviewcomms.ca

Tekmira Pharmaceuticals Logo
Press spacebar to pause and continue. Press esc to stop.